The Experts below are selected from a list of 189 Experts worldwide ranked by ideXlab platform
Ying-chieh Tsai - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Bismuth Subgallate on nitric oxide and prostaglandin E2 production by macrophages
Biochemical and biophysical research communications, 2004Co-Authors: Chia-yen Lin, Yi-hsuan Shen, Chi-hung Lin, Shiaw-min Hwang, Ying-chieh TsaiAbstract:Bismuth Subgallate (BSG) is used widely in clinics, including Vincent's angina, syphilis, and adenotonsillectomy. This study examined the effects of BSG on nitric oxide (NO) and prostaglandin E2 (PGE2) production in activated RAW 264.7 cells. BSG suppressed production of NO and PGE2 in a dose-dependent manner. BSG could increase TGF-beta1 production, which in turn might promote degradation of iNOS mRNA, thus inhibiting NO production. Additionally, BSG inhibited mPGES protein expression and COX-2 activity in activated RAW 264.7 cells. Exogenous addition of SNP reversed the inhibition effect of PGE2 production by BSG. This behavior indicates that PGE2 inhibition by BSG exerts an indirect effect through NO inhibition.
-
synergistic effect of Bismuth Subgallate and borneol the major components of sulbogin on the healing of skin wound
Biomaterials, 2003Co-Authors: Lee-min Mai, Chia-yen Lin, Chia-yen Chen, Ying-chieh TsaiAbstract:Most skin lesions heal delay and even heal efficiently within 1–2 weeks, the healed tissue is neither aesthetically nor functionally perfect. Therefore, facilitating skin healing rate and controlling healed skin quality are major aims of drug treatment for a s wound event. Bismuth Subgallate (BS) and Borneol (BO) are the two components of Sulbogin s , a new Vaseline-based wound healing ointment, one for treating skin wounds. Although BO has antibiotic function, while BS is widely used clinically, neither has been used specifically for wound healing. The experiment described here aimed to study the effect of BS and BO on the healing of skin wounds. This study also compared the effects of BS and BO with Flamazine s cream, which is currently the most popular drug for wound healing in hospitals. Fullthickness wounds (3 cm 3c m 0.2 cm) were created on the back of adult male Sprague–Dawley rats. BS, BO, BS+BO, and Flamazine s were then evenly applied to cheesecloth and placed over the lesion areas. The drug patches were replaced every 2–3 days until the wound areas were completely covered by epidermis in any kinds of drug treatment. The combined BS and BO treatment had the best effect on healing by decreasing lesion area, while increasing granulation tissue formation, re-epithelialization, eating behavior and reconstitution of skin appendages. This investigation showed that BS and BO have a synergistic effect on the skin wound restoration. r 2003 Elsevier Science Ltd. All rights reserved.
-
Synergistic effect of Bismuth Subgallate and borneol, the major components of Sulbogin, on the healing of skin wound.
Biomaterials, 2003Co-Authors: Lee-min Mai, Chia-yen Lin, Chia-yen Chen, Ying-chieh TsaiAbstract:Most skin lesions heal delay and even heal efficiently within 1-2 weeks, the healed tissue is neither aesthetically nor functionally perfect. Therefore, facilitating skin healing rate and controlling healed skin quality are major aims of drug treatment for a wound event. Bismuth Subgallate (BS) and Borneol (BO) are the two components of Sulbogin, a new Vaseline-based wound healing ointment, one for treating skin wounds. Although BO has antibiotic function, while BS is widely used clinically, neither has been used specifically for wound healing. The experiment described here aimed to study the effect of BS and BO on the healing of skin wounds. This study also compared the effects of BS and BO with Flamazine cream, which is currently the most popular drug for wound healing in hospitals. Full-thickness wounds (3 cm x 3 cm x 0.2 cm) were created on the back of adult male Sprague-Dawley rats. BS, BO, BS+BO, and Flamazine were then evenly applied to cheesecloth and placed over the lesion areas. The drug patches were replaced every 2-3 days until the wound areas were completely covered by epidermis in any kinds of drug treatment. The combined BS and BO treatment had the best effect on healing by decreasing lesion area, while increasing granulation tissue formation, re-epithelialization, eating behavior and reconstitution of skin appendages. This investigation showed that BS and BO have a synergistic effect on the skin wound restoration.
Samuel Cottam - One of the best experts on this subject based on the ideXlab platform.
-
Does Bismuth Subgallate Affect Smell and Stool Character? A Randomized Double-Blinded Placebo-Controlled Trial of Bismuth Subgallate on Loop Duodenal Switch Patients with Complaints of Smelly Stools and Diarrhea
Obesity Surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:Background Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. Methods A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. Results Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall ( P = 0.007) and in the digestive domain ( P
-
Does Bismuth Subgallate Affect Smell and Stool Character? A Randomized Double-Blinded Placebo-Controlled Trial of Bismuth Subgallate on Loop Duodenal Switch Patients with Complaints of Smelly Stools and Diarrhea.
Obesity surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall (P = 0.007) and in the digestive domain (P < 0.001) than those obtained before the treatment. GIQLI scores obtained from the other domains were also higher compared to the pre-treatment as well as placebo treatment but not statistically significant. In our double-blinded trial, treatment with BS after LDS statistically improves GIQLI score and steatorrhea-like symptoms.
-
does Bismuth Subgallate affect smell and stool character a randomized double blinded placebo controlled trial of Bismuth Subgallate on loop duodenal switch patients with complaints of smelly stools and diarrhea
Obesity Surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:BACKGROUND Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. METHODS A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. RESULTS Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall (P = 0.007) and in the digestive domain (P < 0.001) than those obtained before the treatment. GIQLI scores obtained from the other domains were also higher compared to the pre-treatment as well as placebo treatment but not statistically significant. CONCLUSION In our double-blinded trial, treatment with BS after LDS statistically improves GIQLI score and steatorrhea-like symptoms.
Thomas Serena - One of the best experts on this subject based on the ideXlab platform.
-
112 Bismuth Subgallate borneal suile vs bacitracin in the human forearm biopsy model for acute wound healing
Wound Repair and Regeneration, 2008Co-Authors: Thomas Serena, L K S Parnell, M Miller, K Shay, M Brown, M WiltAbstract:Background: The human forearm biopsy model is employed by the Wound Healing Cooperative Group to evaluate the effect of novel agents on acute wounds. Bismuth Subgallate/Borneal (Suile) is a new product with FDA permission for the treatment of partial thickness wounds. However, there is a growing body of evidence suggesting that Suile may be effective in the treatment of full thickness wounds because of its antimicrobial, hemostatic and antiinflammatory properties. Methods: In our randomized, investigator-blinded study, 20 normal healthy volunteers underwent two 6 mm full-thickness skin biopsies on the flexor surface of each forearm (two wounds per subject). Biopsy sites were randomly assigned to control (daily bacitracin) or to the treatment arm (daily Suile). The wounds were examined, measured by digital planimetry, and photographed daily until complete healing was achieved. Adverse events and pain levels were monitored. Healing velocity and time-to-complete closure were determined. Results: The forearm biopsy model allowed direct quantitative and qualitative comparisons of wound healing outcomes achieved by the Suile regimen versus bacitracin alone. Subject compliance was excellent. The conduct of the study was further facilitated by the use of handheld electronic documentation. Conclusion: The forearm biopsy model has several advantages: It allows for a direct comparison of topical agents in a controlled fashion, studies can be conducted rapidly with good patient compliance and it allows investigators to gain firsthand experience with products prior to embarking on large clinical trials in chronic wounds. Acknowledgments: Grant from Hedonist Biochemical Technologies Co.
-
Bismuth Subgallate borneol suile is superior to bacitracin in the human forearm biopsy model for acute wound healing
Advances in Skin & Wound Care, 2007Co-Authors: Thomas Serena, Laura K S Parnall, Carrie Knox, Julia Vargo, Amanda Oliver, Sarah Merry, Andrew Klugh, Nicole Bubar, Neil Anderson, Lynn RiemanAbstract:BACKGROUND: The human forearm biopsy model can evaluate the effect of novel agents on acute wounds. Bismuth Subgallate/borneol (Suile) is a new product cleared by the Food and Drug Administration for treating partial-thickness wounds. Anecdotal reports suggest that Suile may be effective for full-thickness wounds because of its antimicrobial and hemostatic properties. METHODS: In a randomized, investigator-blinded study, 20 normal healthy volunteers underwent 2 6-mm full-thickness skin punch biopsies on the flexor surface of each forearm (2 wounds per subject). Biopsies were randomly assigned to control (bacitracin) and test article (Suile). Wounds were examined, measured by digital planimetry, and photographed daily until healed. Adverse events and pain levels were monitored. Time-to-complete closure was determined. RESULTS: Direct quantitative and qualitative comparisons of wound healing were made. The Suile group trended strongly toward more rapid healing (log-rank analysis). Individual subject arm analysis identified which biopsies healed first. Suile-treated biopsies healed more rapidly (P = .03, paired t-test). CONCLUSION: Although this study was powered to demonstrate equivalence, convincing evidence indicates that Suile is superior to bacitracin in this model. Based on the results, future studies in full-thickness wounds with Suile are warranted. The biopsy model provides these advantages: direct comparison within subjects, rapid study completion, good patient compliance, and experience with products before embarking on larger clinical trials in wounds.
-
Bismuth Subgallate/borneol (suile) is superior to bacitracin in the human forearm biopsy model for acute wound healing.
Advances in skin & wound care, 2007Co-Authors: Thomas Serena, Laura K S Parnall, Carrie Knox, Julia Vargo, Amanda Oliver, Sarah Merry, Andrew Klugh, Nicole Bubar, Neil Anderson, Lynn RiemanAbstract:The human forearm biopsy model can evaluate the effect of novel agents on acute wounds. Bismuth Subgallate/borneol (Suile) is a new product cleared by the Food and Drug Administration for treating partial-thickness wounds. Anecdotal reports suggest that Suile may be effective for full-thickness wounds because of its antimicrobial and hemostatic properties. In a randomized, investigator-blinded study, 20 normal healthy volunteers underwent 2 6-mm full-thickness skin punch biopsies on the flexor surface of each forearm (2 wounds per subject). Biopsies were randomly assigned to control (bacitracin) and test article (Suile). Wounds were examined, measured by digital planimetry, and photographed daily until healed. Adverse events and pain levels were monitored. Time-to-complete closure was determined. Direct quantitative and qualitative comparisons of wound healing were made. The Suile group trended strongly toward more rapid healing (log-rank analysis). Individual subject arm analysis identified which biopsies healed first. Suile-treated biopsies healed more rapidly (P = .03, paired t-test). Although this study was powered to demonstrate equivalence, convincing evidence indicates that Suile is superior to bacitracin in this model. Based on the results, future studies in full-thickness wounds with Suile are warranted. The biopsy model provides these advantages: direct comparison within subjects, rapid study completion, good patient compliance, and experience with products before embarking on larger clinical trials in wounds.
Hinali Zaveri - One of the best experts on this subject based on the ideXlab platform.
-
Does Bismuth Subgallate Affect Smell and Stool Character? A Randomized Double-Blinded Placebo-Controlled Trial of Bismuth Subgallate on Loop Duodenal Switch Patients with Complaints of Smelly Stools and Diarrhea
Obesity Surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:Background Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. Methods A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. Results Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall ( P = 0.007) and in the digestive domain ( P
-
Does Bismuth Subgallate Affect Smell and Stool Character? A Randomized Double-Blinded Placebo-Controlled Trial of Bismuth Subgallate on Loop Duodenal Switch Patients with Complaints of Smelly Stools and Diarrhea.
Obesity surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall (P = 0.007) and in the digestive domain (P < 0.001) than those obtained before the treatment. GIQLI scores obtained from the other domains were also higher compared to the pre-treatment as well as placebo treatment but not statistically significant. In our double-blinded trial, treatment with BS after LDS statistically improves GIQLI score and steatorrhea-like symptoms.
-
does Bismuth Subgallate affect smell and stool character a randomized double blinded placebo controlled trial of Bismuth Subgallate on loop duodenal switch patients with complaints of smelly stools and diarrhea
Obesity Surgery, 2018Co-Authors: Hinali Zaveri, Amit Surve, Daniel Cottam, Walter Medlin, Christina Richards, Austin Cottam, Samuel CottamAbstract:BACKGROUND Loop duodenal switch (LDS) can result in fat and starch malabsorption. In a small percentage of patients, a relevant qualitative and quantitative change in stools happens usually characterized by steatorrhea-like diarrhea. Bismuth Subgallate (BS) has been marketed as a way to eliminate the odor associated with flatulence and bowel movements. The objective of this study is to see the efficacy and effect of BS on the quality of life (QOL) in patients undergoing LDS. METHODS A prospective, randomized, double-blinded, placebo-controlled, crossover study was designed. Thirty-six patients who reported flatus and/or stool odor changes and have completed at least 6 months post-LDS were included. Patients participated in two treatment periods, each lasting for 1 week, separated by 1-week washout. Patients received 200 mg BS, 2 capsules per meal, or placebo for 1 week each. The Gastrointestinal Quality of Life Index (GIQLI) questionnaire was used to compare the QOL before the initiation of the therapy and after each treatment completion. RESULTS Of 36 patients, 5 patients were lost to follow-up and 2 were withdrawn from the study. And 29 patients were included for final analysis. GIQLI scores obtained with BS treatment completion were significantly higher both overall (P = 0.007) and in the digestive domain (P < 0.001) than those obtained before the treatment. GIQLI scores obtained from the other domains were also higher compared to the pre-treatment as well as placebo treatment but not statistically significant. CONCLUSION In our double-blinded trial, treatment with BS after LDS statistically improves GIQLI score and steatorrhea-like symptoms.
Randy C. Hatton - One of the best experts on this subject based on the ideXlab platform.
-
Bismuth Subgallate epinephrine paste in adenotonsillectomies
Annals of Pharmacotherapy, 2000Co-Authors: Randy C. HattonAbstract:OBJECTIVE:To evaluate the role of Bismuth Subgallate–epinephrine (BSE) paste as a hemostatic in adenotonsillectomies.DATA SOURCES:MEDLINE (January 1966–October 1999) and Current Contents (January 1997–October 1999) were searched, using Bismuth Subgallate, adenoidectomy, tonsillectomy, and adenotonsillectomy as search terms. A citation search was performed using Science Citation Index (January 1977–October 1999).DATA SYNTHESIS:Adenotonsillectomies are common procedures; although there are few complications, hemorrhage is a concern. Bismuth Subgallate has historically been used as an astringent and hemostatic. An evaluation of studies of Bismuth Subgallate and BSE paste was conducted.CONCLUSIONS:There is minimal evidence to support this practice, but data suggest that epinephrine may be the active ingredient in BSE paste. BSE paste is inexpensive, poses little risk, and may decrease postoperative bleeding; therefore, it may be a reasonable hemostatic agent.
-
Bismuth Subgallate–Epinephrine Paste in Adenotonsillectomies
The Annals of pharmacotherapy, 2000Co-Authors: Randy C. HattonAbstract:OBJECTIVE:To evaluate the role of Bismuth Subgallate–epinephrine (BSE) paste as a hemostatic in adenotonsillectomies.DATA SOURCES:MEDLINE (January 1966–October 1999) and Current Contents (January 1997–October 1999) were searched, using Bismuth Subgallate, adenoidectomy, tonsillectomy, and adenotonsillectomy as search terms. A citation search was performed using Science Citation Index (January 1977–October 1999).DATA SYNTHESIS:Adenotonsillectomies are common procedures; although there are few complications, hemorrhage is a concern. Bismuth Subgallate has historically been used as an astringent and hemostatic. An evaluation of studies of Bismuth Subgallate and BSE paste was conducted.CONCLUSIONS:There is minimal evidence to support this practice, but data suggest that epinephrine may be the active ingredient in BSE paste. BSE paste is inexpensive, poses little risk, and may decrease postoperative bleeding; therefore, it may be a reasonable hemostatic agent.